Related references
Note: Only part of the references are listed.Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis
Pantelis A. Sarafidis et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2010)
Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study
Katerina K. Naka et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Oxidative Stress and Diabetic Complications
Ferdinando Giacco et al.
CIRCULATION RESEARCH (2010)
Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy
L. Monnier et al.
DIABETOLOGIA (2010)
Challenge in diabetes therapy: Effects of thiazolidinediones beyond blood glucose control
G. Schernthaner et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2009)
CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone
D. John Betteridge
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2009)
Markers of inflammation and coronary artery calcification: A systematic review
Yasmin S. Hamirani et al.
ATHEROSCLEROSIS (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Circulating Matrix Metalloproteinase-9 Is Associated with Cardiovascular Risk Factors in a Middle-Aged Normal Population
Peter Garvin et al.
PLOS ONE (2008)
Anti-inflammatory effects of pioglitazone and/or sinivastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein -: The PIOSTAT study
Markolf Hanefeld et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Diabetes treatments have differential effects on nontraditional cardiovascular risk factors
VA Fonseca et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2006)
Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study
V Mattoo et al.
CLINICAL THERAPEUTICS (2005)
Serum metalloproteinase 9 levels in patients with coronary artery disease: A novel marker of inflammation
P Ferroni et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2003)
Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease
S Blankenberg et al.
CIRCULATION (2003)
Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in pa with acute coronary syndrome
Y Inokubo et al.
AMERICAN HEART JOURNAL (2001)
Share Paper
